Citadel Advisors
ADIL

Citadel Advisors’s Adial Pharmaceuticals ADIL Stock Holding History

Citadel Advisors’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-34
Closed -$28K – 12498
2022
Q2 		$28K Buy
+34
New +$30.8K ﹤0.01% 12254
2022
Q1 		– Sell
-62
Closed -$105K – 13463
2021
Q4 		$105K Buy
+62
New +$122K ﹤0.01% 12668

Other funds holding ADIL

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCM
Manchester Capital Management Manchester, Vermont $768M AUM 29.32% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors's ADIL Position: Q2 2026 in Review

Citadel Advisors opened a new position in Adial Pharmaceuticals (ADIL) in Q2 2026: 29,547 shares worth $75.6K. The stake represents ﹤0.01% of the portfolio and ranks #12873 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ADIL as recently as Q4 2025.

Citadel Advisors first reported a position in ADIL in Q1 2019 and has held it in 11 quarters since. The position peaked at $180K in Q1 2021. 17 funds tracked by Wall St. Rank hold ADIL as of Q2 2026.

  • Citadel Advisors held 29,547 shares of Adial Pharmaceuticals worth $75.6K as of Q2 2026.
  • Adial Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • Adial Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12873 holding.
  • Citadel Advisors first reported a position in Adial Pharmaceuticals in Q1 2019 and has held it in 11 quarters since.
  • Citadel Advisors's Adial Pharmaceuticals position peaked at $180K in Q1 2021.
  • 17 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.